The aim of this study was to assess the association between the third component of the complement (C3) and other risk factors of coronary heart disease.
Methods and results
We evaluated 1200 individuals aged 25–74 years (600 men and 600 women). A strong relationship was shown between serum C3 and both body mass index (BMI, P<0.01) and fibrinogen (P<0.01). We found a significant, independent correlation with: platelet count (P<0.01), insulin level (P<0.01), triglycerides (P<0.01), low-density lipoprotein (LDL) cholesterol (P<0.01), and an inverse correlation with cigarette smoking (P<0.01).
Conclusions
A high concentration of C3 is a marker of a profile at risk of atherogenesis.
LiuzzoGBiasucciLMGallimoreJRGrilloRLRebuzziAGPepysMBMaseriA. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med1994; 331:417–424.
2.
MendallMAStrachanDPButlandBKBallamLMorrisJSweetnamPMElwoodPC. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J2000; 21:1584–1590.
3.
MaseriA. C-reactive protein in cardiovascular risk prediction. Zooming in and zooming out. Ital Heart J2001; 2:155–156.
4.
LagrandWKVisserCAHermensWTNiessenHWVerheugtFWWolbinkGJHackCE. C-Reactive protein as a cardiovascular risk factor. More than an epiphenomena?Circulation1999; 6:96–102.
5.
FriedmanGDTekawaIGrimmRHManolioTShannonSGSidneyS. The leukocyte count: correlates and relationship to coronary risk factors: the CARDIA study. Int J Epidemiol1990; 19:889–893.
6.
ZalokarGBRichardJLClaudeJR. Leukocyte count, smoking and myocardial infarction. N Engl J Med1981; 304:465–468.
7.
GrimmRHNeatonJDLudwigW. Prognostic importance of the white blood cell count for coronary, cancer, and all cause mortality. JAMA1985; 254:1932–1937.
8.
De LabryLOCampionEWGlynnRJVokonasPS. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. J Clin Epidemiol1990; 43:153–157.
9.
YarnellJWGBakerIASweetnamPMBaintonDO'BrienJRWhiteadPJElwoodPC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation1991; 83:836–844.
10.
MuscariABozzoliCPudduGMSangiorgiZDormiARovinettiCAssociation of serum C3 levels with the risk of myocardial infarction. Am J Med1995; 98:375–364.
11.
MuscariAMassarelliGBastagliLPoggiopolliniGTomassettiVVoltaURelationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol1998; 53:345–354.
12.
YlitaloKPorkkaKVKMeriSNuotioISuurin KeroinenLVakkilainenJSerum complement and familial combined hyperlipidemia. Atherosclerosis1997; 129:271–277.
13.
UzaGCristeaACucuianuMP. Increased levels of the complement C3 protein in endogenous hypertriglyceridemia. J Clin Lab Immunol1982; 8:101–105.
14.
BozzoliCMuscariAPudduGMRovinettiCRenziCVallarGPudduP. Associazione fra C3 sierico e ipertensione essenziale. G Ital Cardiol1992; 22:1361–1366.
15.
MuscariABozzoliCPudduGMRovinettiCFiorentiniGPRoversiRAPudduP. Correlations between serum lipids and complement components in adults without demonstrated atherosclerosic disease. Atherosclerosis1990; 81:111–118.
16.
CapuanoVD'ArminioTBambacaroALanzaraCD'AntonioV. II Progetto VIP: prevalenza dei fattori di rischio della cardiopatia ischemica in un'area della Campania. Ital Heart J Suppl2001; 2:1201–1208.
17.
WHO.CINDI Programme–Protocol and Guidelines. Copenhagen: WHO Regional Office for Europe; 1996.
18.
MenottiAGiampaoliSVerdecchiaACesanaGCFeruglioGARighettiGII Progetto MONICA (monitoraggio malattie cardiovascolari). Protocollo e manuale delle aree italiane. Roma rapporti Istisan/ISTISAN89/12, 1989.
19.
ChoyLNRosenBSSpiegelmanBM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem1992; 267:12736–12741.
20.
YudkinJS. Relationship of serum C3 complement with insulin resistance and coronary heart disease–cause, consequence or common antecedent?Eur Heart J2000; 21:1081–1090.
21.
ReavenGM. Insulin resistance, hyperinsulinemia, hypertrigliceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care1991; 14:195–202.
22.
YudkinJS. Abnormalities of coagulation and fibrinolysis in insulin resistance: evidence for a common antecedent?Diabetes Care1999; 22:C25–C30.
23.
YudkinJSStehouwerCDAEmeisJJCoppackSW. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol1999; 19:972–978.
24.
MuscariAMassarelliGBastagliLPoggiopolliniGTomassettiVDragoGRelationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle aged men. Eur Heart J2000; 21:1081–1090.
25.
RuigeJBAssendelftWJDekkerJMKostensePJHeineRJBouterLM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation1998; 97:996–1001.
26.
HalkesCJMvan DijkHde JaegerePPTPlokkerHWvan Der HelmYErkelensDWCastro CabezasM. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease. Effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol2001; 21:1526–1530.
27.
TanhehcoEJLucchesiBR. Therapeutic potential of complement inhibitors in myocardial ischaemia. Expert Opin Invest Drugs2000; 9:975–991.
